Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Prognostic factors of atypical meningiomas treated with gross total resection and early radiotherapy: microRNA-221/222 co-modulated radiosensitivity regulatory mechanism and malignent progression

ABSTRACT: Prognostic factors of atypical meningiomas treated with gross total resection and early radiotherapy: microRNA-221/222 co-modulated radiosensitivity regulatory mechanism and malignent progression

PROVIDER: PRJNA475026 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Prognostic factors of atypical meningiomas treated with gross total resection and early radiotherapy: microRNA-221/222 co-modulated radiosensitivity regulatory mechanism and malignent progression

Project description:Background. The impact of adjuvant radiation therapy (XRT) after gross-total resection (GTR) of atypical meningiomas (AMs) has always been controversial. Considering that intrinsic differences among these AMs may exist, our study aim to seek which kind of these patients is more likely to recur and to explore its underlying causes. Methods. The case database and the pathological records of our hospital between Jan 2008 and Jul 2016 were reviewed, 46 AMs received early XRT after GTR (confirmed by the 2016 revision of WHO diagnostic criteria). Microarray analysis and quantitative real-time polymerase chain reaction (qRT-PCR) were performed to detect aberrant expression of microRNAs (miRs). Immunohistochemical staining for the biomarker was performed, and its expression was semi-quantitative analyzed by using Image Pro Plus (IPP) 6.0. Univariate and multivariate Cox proportional hazards regression analysis were used to assess the correlation between various factors and recurrence. Results. Microarray analysis and qRT-PCR demonstrated that miR-221/222 were upregulated in radiotherapy resistance (RTR) AM tissues compared with radiotherapy sensitive (RTS) AM tissues. Multivariable analysis showed that malignant progression (MP) (P=0.011), low expression level of PTEN (P=0.026) and skull-base AMs (P=0.028) were associated with higher recurrence. Conclusion. We first demonstrated that upregulated miR-221/222 could decrease the radiosensitivity of the combination-therapy-treated AMs. Meanwhile, AMs with low expression level of PTEN, skull-base located were more likely to recur. MP-AMs were associated with increased possibility of recurrence by comparing to primary AMs. Treatment and consideration of MP-meningiomas were advocated to refer to the therapeutic strategy for higher grade meningiomas rather than restricted to its present grade.

2021-06-06 | GSE115444 | GEO

Antisense miRNA-221/222 (si221/222) and control inhibitor (GFP) treated fulvestrant-resistant breast cancer cells

2011-01-29 | GSE19777 | GEO

Gene expression profiling of MCF10A (miR-221/222 vs control)

Project description:Analysis of gene expression of MCF10A to identify the targets of miR-221 and miR-222 Keywords: MCF10, miR-221, miR-222

2011-06-14 | GSE29327 | GEO

Gene expression profiling of MCF10A (miR-221/222 vs control)

Project description:Analysis of gene expression of MCF10A to identify the targets of miR-221 and miR-222 Keywords: MCF10, miR-221, miR-222 RNA profiles of human MCF10A cell line

2011-06-14 | E-GEOD-29327 | biostudies-arrayexpress

Antisense miRNA-221/222 (si221/222) and control inhibitor (GFP) treated fulvestrant-resistant breast cancer cells

Project description:Full title: Expression data from antisense miRNA-221/222 (si221/222) and control inhibitor (GFP) treated fulvestrant-resistant breast cancer cells The expression of miR-221/222 were found to be upregulated in fulvestrant resistant breast cancer cells MCF7-FR compared to its drug-sensitive counterpart MCF7. To investigate the role of miR-221/222 in acquired resistance to fulvestrant, we lowered the level of miR-221/222 in MCF7-FR cells using miRNA inhibitors (antagomirs), and compared gene expression profiles before and after treatment. Fulvestrant-resistant breast cancer cells MCF7-FR (originated from drug-sentitive breast cancer model cell line MCF7) were transient-transfected by antigomirs targeting miR221 or miR222 (i.e. si221, si222). All three cell lines, MCF7-FR, siR221, siRNA222 were subjected to gene expression profiling.

2011-01-29 | E-GEOD-19777 | biostudies-arrayexpress

miR-221/222 drive synovial fibroblast expansion and pathogenesis of TNF-mediated arthritis

Project description:MicroRNAs (miRNAs) constitute fine tuners of gene expression and are implicated in a variety of diseases spanning from inflammation to cancer. miRNA expression is deregulated in rheumatoid arthritis (RA), however, their specific role in key arthritogenic cells such as the synovial fibroblast (SF) remains elusive. We have shown in the past that the expression of the miR-221/222 cluster is upregulated in RA SFs. Here, we demonstrate that miR-221/222 activation is downstream of major inflammatory cytokines, such as TNF and IL-1β, which promote miR-221/222 expression independently. miR-221/222 expression in SFs from the huTNFtg mouse model of arthritis correlates with disease progression. Targeted transgenic overexpression of miR-221/222 in SFs of the huTNFtg mouse model led to further expansion of synovial fibroblasts and disease exacerbation. miR-221/222 overexpression altered the transcriptional profile of SFs igniting pathways involved in cell cycle progression and ECM regulation. Validated targets of miR-221/222 included p27 and p57 cell cycle inhibitors, as well as Smarca1 (a chromatin remodeling component). In contrast, complete genetic ablation of miR-221/222 in arthritic mice led to decreased proliferation of fibroblasts, reduced synovial expansion and attenuated disease. scATAC-seq data analysis revealed increased miR-221/222 gene activity in the pathogenic and activated clusters of the intermediate and lining compartment. Taken together, our results establish an SF-specific pathogenic role of the miR-221/222 cluster in arthritis and suggest that its therapeutic targeting in specific subpopulations should inform the design of novel fibroblast-targeted therapies for human disease.

2022-12-16 | GSE210887 | GEO

Identification of genes differentially expressed in lung cancer cells after the transfection of miR-221 or miR-222.

Project description:To evaluate involvement of miR-221 and miR-222 in lung cancer, we investigated the effects of miR-221 and miR-222 overexpression on six lung cancer cell lines as well as one immortalized normal human bronchial epithelial cell line. Two cell lines, H3255 and H1299 with no replicates were studied. Cells were transfected with miR-221, miR-222, or miR control. Microarray analysis was done to identify genes differentially expressed in lung cancer cells after the transfection of miR-221 or miR-222.

2015-05-22 | E-GEOD-57676 | biostudies-arrayexpress

Identification of genes differentially expressed in lung cancer cells after the transfection of miR-221 or miR-222.

2015-05-22 | GSE57676 | GEO

MiR-221/222 suppression induced by activation of the cAMP/PKA/CREB1 pathway is required for cAMP-induced bidirectional differentiation of glioma cells [miRNA]

Project description:Factors that increase cAMP levels can induce lineage-specific differentiation of glioma cells into astrocyte-like cells. However, the differentiation pattern and underlying mechanisms remain unclear. Here, we find that cAMP/PKA/CREB1-induced miR-221/222 suppression contributes to the neuron-like differentiation of gliomas. cAMP agonists selectively induced neuron- and astrocyte-like but not oligodendrocyte-like differentiation of C6 glioma cells. PKA inhibitors and CREB1 knockout blocked neuron-like differentiation of glioma cells. cAMP inhibited miR-221/222 in a PKA/CREB1 dependent manner. Importantly, both in vitro and in vivo assays demonstrated that transcriptional suppression of miR-221/222 is required for neuronal differentiation of glioma cells. Our findings suggest that increasing cAMP levels can induce bidirectional differentiation of glioma cells. Furthermore, the miR-221/222 cluster acts as an epigenetic brake during glioma differentiation. Factors that increase cAMP levels can induce lineage-specific differentiation of glioma cells into astrocyte-like cells. However, the differentiation pattern and underlying mechanisms remain unclear. Here, we find that cAMP/PKA/CREB1-induced miR-221/222 suppression contributes to the neuron-like differentiation of gliomas. cAMP agonists selectively induced neuron- and astrocyte-like but not oligodendrocyte-like differentiation of C6 glioma cells. PKA inhibitors and CREB1 knockout blocked neuron-like differentiation of glioma cells. cAMP inhibited miR-221/222 in a PKA/CREB1 dependent manner. Importantly, both in vitro and in vivo assays demonstrated that transcriptional suppression of miR-221/222 is required for neuronal differentiation of glioma cells. Our findings suggest that increasing cAMP levels can induce bidirectional differentiation of glioma cells. Furthermore, the miR-221/222 cluster acts as an epigenetic brake during glioma differentiation.

2021-08-24 | GSE182498 | GEO

Determining miR-221/222-3p targets in B cells activated with aCD40 IL4 IL21 in vitro

Project description:compared miR-221/222-3p deficient (KO) and WT (Flox) activated B cell mRNAseq and Ago2-HITSCLIP to determine mRNA targets of this miRNA cluster

2021-01-01 | GSE153811 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data